Biocurious: For Recce, our near neighbour was the obvious place to launch a diabetes-related trial Posted on April 3, 2025 by recce_com Biocurious: For Recce, our near neighbour was the obvious place to launch a diabetes-related trial
Synthetic Gel Shows Utility Across ABSSSI, Company Sees Other Indications Posted on March 6, 2025 by recce_com Synthetic Gel Shows Utility Across ABSSSI, Company Sees Other Indications
Australian biotech points to potential superbug use as gel treats skin infections in phase 2 trial Posted on February 20, 2025April 3, 2025 by recce_com Australian biotech points to potential superbug use as gel treats skin infections in phase 2 trial
Recce soars on phase II skin infection trial results Posted on February 17, 2025 by recce_com Recce soars on phase II skin infection trial results
Recce Pharmaceuticals doses all patients in phase II skin infection trial Posted on January 29, 2025 by recce_com Recce Pharmaceuticals doses all patients in phase II skin infection trial
Recce Pharmaceuticals doses all patients in Phase 2 clinical trial of RECCE® 327 topical gel for skin infections Posted on January 21, 2025 by recce_com Recce Pharmaceuticals doses all patients in Phase 2 clinical trial of RECCE® 327 topical gel for skin infections
Recce gets Indonesian nod for phase III trial of diabetic foot infection treatment Posted on December 9, 2024 by recce_com Recce gets Indonesian nod for phase III trial of diabetic foot infection treatment
Complete patent protection for 2 Recce anti-infective treatments Posted on November 26, 2024 by recce_com Complete patent protection for 2 Recce anti-infective treatments
Recce green lit to begin dosing in registrational Phase 3 trial for diabetic foot infections Posted on November 11, 2024 by recce_com Recce green lit to begin dosing in registrational Phase 3 trial for diabetic foot infections
From No More Tears to no more superbug fears Posted on October 21, 2024 by recce_com From No More Tears to no more superbug fears
